Marked increase of CD5 + B cells in hyperthyroid Graves' disease

Area of Science:

• Immunology
• Endocrinology
• Thyroid Disease Research

Background:

• CD5+ B lymphocytes are implicated in autoantibody production.
• Thyroid diseases, including Graves' disease and Hashimoto's thyroiditis, involve immune system dysregulation.
• Accurate diagnosis and monitoring of thyroid conditions are crucial for effective treatment.

Purpose of the Study:

• To investigate the proportion of CD5+ B cells in patients with various thyroid diseases.
• To determine if CD5+ B cell levels can serve as a diagnostic or therapeutic marker for Graves' disease.

Main Methods:

• Peripheral blood samples were collected from patients with different thyroid conditions.
• Flow cytometry was used to quantify CD5+ B cells.
• Serum levels of thyroid hormones, thyroid-stimulating hormone receptor antibody (TRAb), and thyroid-stimulating hormone (TSH) were measured.

Main Results:

• Markedly elevated CD5+ B cells (>9.0%) were observed in untreated hyperthyroid Graves' disease patients compared to normal ranges (0.5-7.7%).
• CD5+ B cell levels correlated with thyroid hormones and TRAb in active Graves' disease.
• Normal CD5+ B cell levels were found in patients with destructive thyrotoxicosis (Hashimoto's or subacute thyroiditis).
• Treatment of hyperthyroidism led to decreased CD5+ B cells and TRAb levels.

Conclusions:

• The proportion of CD5+ B cells is a valuable diagnostic marker for differentiating Graves' disease from destructive thyrotoxicosis.
• CD5+ B cell levels can serve as a therapeutic index for monitoring Graves' disease management.
• Increased CD5+ B cells are specifically associated with Graves' disease pathogenesis.